Reduced occurrence of severe visual impairment after introduction of anti-Vascular Endothelial Growth Factor in wet age-related macular degeneration – a population- and register-based study from northern Sweden

Acta Ophthalmologica

Volumn 94, Issue 7, 2016, Pages 646-651

  Granstam, Elisabet ^a   Westborg, Inger ^b   Barkander, Anna ^c   Börjesson, Malin ^d   Lindahl, Sara ^e   Meszaros, Eva ^f   Wojciechowska Zajac, Anna ^g   Wagner, Philippe ^a   Albrecht, Susanne ^h   Karlsson, Niklas ^h   Bjärnhall, Gunilla ^h   Lövestam Adrian, Monica ⁱ  

^a UPPSALA UNIVERSITY   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

^c ÖSTERSUND HOSPITAL   (Sweden)

^d Sweden   (Sweden)

^e UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^f Gavle Sandviken County Hospital   (Sweden)

^g Sunderby County Hospital   (Sweden)

^h RC Syd   (Sweden)

ⁱ LUND UNIVERSITY   (Sweden)

Author keywords

anti vascular endothelial growth factor; low vision clinics; Swedish Macula Register; wet AMD

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN ANTIBODY; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGE; AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; DISEASE SEVERITY; FEMALE; HIGH RISK PATIENT; HUMAN; LOW VISION; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; REGISTER; SWEDEN; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL IMPAIRMENT; ANTAGONISTS AND INHIBITORS; FOLLOW UP; INCIDENCE; INTRAVITREAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR; STATISTICS AND NUMERICAL DATA; VERY ELDERLY; VISION, LOW; VISUALLY IMPAIRED PERSON; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INTRAVITREAL INJECTIONS; MALE; REFERRAL AND CONSULTATION; REGISTRIES; RISK FACTORS; SWEDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISION, LOW; VISUAL ACUITY; VISUALLY IMPAIRED PERSONS; WET MACULAR DEGENERATION;

EID: 84991585512     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/aos.13187     Document Type: Article

References (24)

1. van Asten F, Evers-Birkenkamp KU, van Lith-Verhoeven JJC et al. (2015): A prospective, observational, open-label, multicentre study to investigate the daily treatment practice of ranibizumab in patients with neovascular age-related macular degeneration. Acta Ophthalmol 93: 126–133.
2. Bloch SB, Larsen M & Munch IC (2012): Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am J Ophthalmol 153: 209–213.
3. Borooah S, Jeganathan VS, Ambrecht AM, Oladiwura D, Gavin M, Dhillon B & Cackett P (2015): Long-term visual outcomes of intravitreal ranibizumab treatment for wet age-related macular degeneration and effect on blindness rates in south-east Scotland. Eye 29: 1156–1161.
4. Bourne RR, Jonas JB, Flaxman SR et al. (2014): Prevalence and causes of vision loss in high-income countries and in eastern and central Europe: 1990–2010. Br J Ophthalmol 98: 629–638.
5. Frennesson CI & Nilsson SE (2014): A three-year follow-up of ranibizumab treatment of exudative AMD: impact on the outcome of carrying forward the last acuity observation in drop-outs. Acta Ophthalmol 92: 216–220.
6. Friedman DS, O'Colmain BJ, Munoz B et al. (2004): Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 122: 564–572.
7. Gangnon RE, Lee KE, Klein BEK, Iyengar SK, Sivakumaran TA & Klein R (2015): Severity of age-related macular degeneration in 1 eye and the incidence and progression of age-related macular degeneration in the fellow eye. The Beaver Dam Eye Study. JAMA Ophthalmol 133: 125–132.
8. Håkansson I, Lundström M, Stenevi U & Ehinger B (2001): Data reliability and structure in the Swedish National Cataract Register. Acta Ophthalmol Scand 79: 518–523.
9. Heier JS, Brown DM, Chong V et al. (2012): Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119: 2537–2548.
10. Hjelmqvist L, Lindberg C, Kanulf P, Dahlgren H, Johansson I & Siewert A (2011): One-year outcomes using ranibizumab for neovascular age-related macular degeneration: results of a prospective and retrospective observational multicentre study. J Ophthalmol 2011: 405724 [Epub ahead of print].
11. Holladay JT (1997): Proper method for calculating average visual acuity. J Refract Surg 13: 388–391.
12. Holz FG, Tadayoni R, Beatty S et al. (2015): Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol 99: 220–226.
13. Lindekleiv H & Erke MG (2013): Projected prevalence of age-related macular degeneration in Scandinavia 2012–2040. Acta Ophthalmol 91: 307–311.
14. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ & The CATT Research Group (2011): Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364: 1897–1908.
15. NYSAM (Nyckeltal i samverkan) statistics (2014): Low vision clinics. www.nysam.com/report/form
16. Rasmussen A, Brandi S, Fuchs J, Hansen LH, Lund-Andersen H, Sander B & Larsen M (2015): Visual outcomes in relation to time to treatment in neovascular age-related macular degeneration. Acta Ophthalmol 93: 616–620.
17. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY & Kim RY (2006): Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355: 1419–1431.
18. Rudnicka AR, Kapetanakis VV, Jarrar Z, Wathern AK, Wormald R, Fletcher AE, Cook DG & Owen CG (2015): Incidence of late-stage age-related macular degeneration in American whites: systematic review and meta-analysis. Am J Ophthalmol 160: 85–93.
19. Rung L & Lövestam-Adrian M (2013): Three-year follow-up of visual outcome and quality of life in patients with age-related macular degeneration. Clin Ophthalmol 7: 395–401.
20. Skaat A, Chetrit A, Belkin M, Kinori M & Kalter-Leibovici O (2012): Time trends in the incidence and causes of blindness in Israel. Am J Ophthalmol 153: 214–221.
21. Soubrane G, Cruess A, Lotery A et al. (2007): Burden and health care resource utilization in neovascular age-related macular degeneration. Findings of a multicountry study. JAMA Ophthalmol 125: 1249–1254.
22. Statistics Sweden (2015): www.statistikdatabasen.scb.se
23. Sullivan KM, Dean A & Soe MM (2009): OpenEpi: a web-based epidemiologic and statistical calculator for public health. Public Health Reps 124: 471–474.
24. Swedish Macula Register (2013): Yearbook. http://rcsyd.se/anslutna-register/makularegistret